Atreca (BCEL)
(Delayed Data from OTC)
$0.09 USD
-0.01 (-6.24%)
Updated May 3, 2024 03:49 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Atreca, Inc. [BCEL]
Reports for Purchase
Showing records 21 - 40 ( 159 total )
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Clinical Data Update from Lead Asset in 1Q23
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Relevant Abstracts at SITC 2022
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; ATRC-101 and ATRC-301 Gear up For Data Readouts in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ATRC-101 Ph 1b update in 2H:22; ATRC-301 IND in 2H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Clinical Data from Lead Program Remains in 2H2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Smart Defensive Move with Key Catalysts Remaining for 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; EphA2 Candidate Announced, Updates on ATRC-101 in 2H:22
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Pipeline Develops Towards Key Updates With Solid Cash
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
1Q22: Additional Clinical Data from ead Program in 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T